Hubbry Logo
InsomniaInsomniaMain
Open search
Insomnia
Community hub
Insomnia
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Insomnia
Insomnia
from Wikipedia

Insomnia
Other namesSleeplessness, trouble sleeping
Depiction of insomnia from the 14th century medical manuscript Tacuinum Sanitatis
Pronunciation
SpecialtyPsychiatry, Clinical Psychology, Sleep Medicine
SymptomsTrouble sleeping, daytime sleepiness, low energy, irritability, depressed mood[1]
CausesUnknown, psychological stress, chronic pain, heart failure, hyperthyroidism, heartburn, restless leg syndrome, obstructive sleep apnea, others[2]
Diagnostic methodBased on symptoms, sleep study[3]
Differential diagnosisDelayed sleep phase disorder, restless leg syndrome, sleep apnea, psychiatric disorder[4]
TreatmentSleep hygiene, cognitive behavioral therapy, hypnotics[5][6][7]
Frequency~20%[8][9][10]

Insomnia, also known as sleeplessness, is a sleep disorder causing difficulty falling asleep or staying asleep for as long as desired.[1][9][11] Insomnia is typically followed by daytime sleepiness, low energy, irritability, and a depressed mood.[1] It may result in an increased risk of accidents as well as problems focusing and learning.[9] Insomnia can be short-term, lasting for days or weeks, or long-term, lasting more than a month.[1] The concept of the word insomnia has two distinct possibilities: insomnia disorder or insomnia symptoms.[12]

Insomnia can occur independently or as a result of another problem.[2] Conditions that can result in insomnia include psychological stress, chronic pain, heart failure, hyperthyroidism, heartburn, restless leg syndrome, menopause, certain medications, and drugs such as caffeine, nicotine, and alcohol.[2][8] Risk factors include working night shifts and sleep apnea.[9] Diagnosis is based on sleep habits and an examination to look for underlying causes.[3] A sleep study may be done to look for underlying sleep disorders.[3] Screening may be done with questions like "Do you experience difficulty sleeping?" or "Do you have difficulty falling or staying asleep?"[9]

Cognitive behavioral therapy is considered the first-line treatment.[6][13][14] Sleep hygiene and lifestyle changes are also recommended for insomnia, though their efficacy is not definitely established.[5][7][14] Sleep hygiene includes a consistent bedtime, a quiet and dark room, exposure to sunlight during the day and regular exercise.[7] Sleeping pills can improve sleep, though some are associated with falls, cognitive impairment, and dependence.[5][6] These medications are not recommended for more than four or five weeks but can be used longer in certain instances.[6][15] Among these, lemborexant and eszopiclone have the most favorable efficacy and safety profiles.[16] The efficacy and safety of alternative medicine treatments are unclear.[6][15]

Between 10% and 30% of adults have insomnia at any given point in time, and up to half of people have insomnia in a given year.[8][9][10] About 6% of people have insomnia that is not due to another problem and lasts for more than a month.[9] People over the age of 65 are affected more often than younger people.[7] Women are more often affected than men.[8] Descriptions of insomnia occur at least as far back as ancient Greece.[17]

Signs and symptoms

[edit]
Potential complications of insomnia[18]

Symptoms of insomnia:[19]

  • Difficulty falling asleep, including difficulty finding a comfortable sleeping position
  • Waking during the night, being unable to return to sleep[20] and waking up early
  • Not able to focus on daily tasks, difficulty in remembering
  • Daytime sleepiness, irritability, depression or anxiety
  • Feeling tired or having low energy during the day[21]
  • Trouble concentrating
  • Being irritable, acting aggressive, or impulsive

Sleep onset insomnia is difficulty falling asleep at the beginning of the night, often a symptom of anxiety disorders. Delayed sleep phase disorder can be misdiagnosed as insomnia, as sleep onset is delayed much later than normal, while awakening spills over into daylight hours.[22]

It is common for patients who have difficulty falling asleep to also have nocturnal awakenings with difficulty returning to sleep.[23] Two-thirds of these patients wake up in the middle of the night, with more than half having trouble falling back to sleep after a middle-of-the-night awakening.[24]

Early morning awakening occurs earlier (more than 30 minutes) than desired, with an inability to go back to sleep and before total sleep time reaches 6.5 hours. Early morning awakening is often a characteristic of depression.[25] Anxiety symptoms may well lead to insomnia. Some of these symptoms include psychological stress, compulsive worrying about the future, feeling overstimulated, and overanalyzing past events.[26]

Poor sleep quality

[edit]

Poor sleep quality can occur as a result of, for example, restless legs, sleep apnea, or major depression. Poor sleep quality is defined as the individual not reaching stage 3 or delta sleep, which has restorative properties.[27]

Major depression leads to alterations in the function of the hypothalamic–pituitary–adrenal axis, causing excessive release of cortisol, which can lead to poor sleep quality.

Nocturnal polyuria, excessive night-time urination, can also result in a poor quality of sleep.[28]

Subjectivity

[edit]

Some types of insomnia are not classified as insomnia in the usual sense since patients with sleep state misperception frequently sleep for a typical period of time.[29] The problem is that, despite sleeping for multiple hours each night and typically not experiencing significant daytime sleepiness or other symptoms of sleep loss, they do not feel like they have slept very much, if at all.[29] Because their perception of their sleep is incomplete, they incorrectly believe it takes them an abnormally long time to fall asleep, and they underestimate how long they stay asleep.[29]

Problematic digital media use

[edit]
Sleep quality and screen time or digital media use have been linked, including studies looking at media type, time of day, and age of person.[30][31][32][33][34][35][36][37][38][39] Various sleep challenges or outcomes have been studied including a reduction in sleep duration, increased sleep onset latency, modifications to rapid eye movement sleep and slow-wave sleep, increased sleepiness and self-perceived fatigue, and impaired post-sleep attention span and verbal memory.[40]

Causes

[edit]

While insomnia can be caused by many conditions, it can also occur without any identifiable cause. This is known as Primary Insomnia.[41] Primary Insomnia may also have an initial identifiable cause but continues after the cause is no longer present. For example, a bout of insomnia may be triggered by a stressful work or life event. However, the condition may continue after the stressful event has been resolved. In such cases, the insomnia is usually perpetuated by the anxiety or fear caused by the sleeplessness itself, rather than any external factors.[42]

Symptoms of insomnia can be caused by or associated with:

Sleep studies using polysomnography have suggested that people who have sleep disruption have elevated night-time levels of circulating cortisol and adrenocorticotropic hormone.[59] They also have an elevated metabolic rate, which does not occur in people who do not have insomnia but whose sleep is intentionally disrupted during a sleep study. Studies of brain metabolism using positron emission tomography (PET) scans indicate that people with insomnia have higher metabolic rates by night and by day. The question remains whether these changes are the causes or consequences of long-term insomnia.[60]

Genetics

[edit]

Heritability estimates of insomnia vary between 38% in males to 59% in females.[61] A genome-wide association study (GWAS) identified 3 genomic loci and 7 genes that influence the risk of insomnia and showed that insomnia is highly polygenic.[62] In particular, a strong positive association was observed for the MEIS1 gene in both males and females. This study showed that the genetic architecture of insomnia strongly overlaps with psychiatric disorders and metabolic traits.

It has been hypothesized that epigenetics might also influence insomnia through a controlling process of both sleep regulation and brain-stress response, having an impact as well on brain plasticity.[63]

Substance-induced

[edit]

Alcohol-induced

[edit]

Alcohol is often used as a form of self-treatment for insomnia to induce sleep. However, alcohol use to induce sleep can be a cause of insomnia. Long-term use of alcohol is associated with a decrease in NREM stage 3 and 4 sleep as well as suppression of REM sleep and REM sleep fragmentation. Frequent moving between sleep stages occurs with awakenings due to headaches, the need to urinate, dehydration, and excessive sweating. Glutamine rebound also plays a role when someone is drinking; alcohol inhibits glutamine, one of the body's natural stimulants. When the person stops drinking, the body tries to make up for lost time by producing more glutamine than it needs.

The increase in glutamine levels stimulates the brain while the drinker is trying to sleep, keeping them from reaching the deepest levels of sleep.[64] Stopping chronic alcohol use can also lead to severe insomnia with vivid dreams. During withdrawal, REM sleep is typically exaggerated as part of a rebound effect.[65]

Caffeine

[edit]

Some people experience sleep disruption or anxiety if they consume caffeine.[66] Doses as low as 100 mg/day, such as a 6 oz (170 g) cup of coffee or two to three 12 oz (340 g) servings of caffeinated soft-drink, may continue to cause sleep disruption, among other intolerances. Non-regular caffeine users have the least caffeine tolerance for sleep disruption.[67] Some coffee drinkers develop tolerance to its undesired sleep-disrupting effects, but others apparently do not.[68]

Benzodiazepine-induced

[edit]

Like alcohol, benzodiazepines, such as alprazolam, clonazepam, lorazepam, and diazepam, are commonly used to treat insomnia in the short-term (both prescribed and self-medicated), but worsen sleep in the long-term. While benzodiazepines can put people to sleep (i.e., inhibit NREM stage 1 and 2 sleep), while asleep, the drugs disrupt sleep architecture: decreasing sleep time, delaying time to REM sleep, and decreasing deep slow-wave sleep (the most restorative part of sleep for both energy and mood).[69][70][71]

Opioid-induced

[edit]

Opioid medications such as hydrocodone, oxycodone, and morphine are used for insomnia that is associated with pain due to their analgesic properties and hypnotic effects. Opioids can fragment sleep and decrease REM and stage 2 sleep. By producing analgesia and sedation, opioids may be appropriate in carefully selected patients with pain-associated insomnia.[48] However, dependence on opioids can lead to long-term sleep disturbances.[72]

Risk factors

[edit]

Insomnia affects people of all age groups, but people in the following groups have a higher chance of acquiring insomnia:[73]

  • Individuals older than 60
  • History of mental health disorders, including depression, etc.
  • Emotional stress
  • Working late-night shifts
  • Traveling through different time zones[11]
  • Having chronic diseases such as diabetes, kidney disease, lung disease, Alzheimer's, or heart disease[74]
  • Alcohol or drug use disorders
  • Gastrointestinal reflux disease
  • Heavy smoking
  • Work stress[75]
  • Individuals of low socioeconomic status[76]
  • Urban neighborhoods[76]
  • Household stress[76]

Mechanism

[edit]

Two main models exist regarding the mechanism of insomnia: cognitive and physiological. The cognitive model suggests that rumination and hyperarousal contribute to preventing a person from falling asleep and might lead to an episode of insomnia.

The physiological model is based upon three major findings in people with insomnia; firstly, increased urinary cortisol and catecholamines have been found suggesting increased activity of the HPA axis and arousal; second, increased global cerebral glucose utilization during wakefulness and NREM sleep in people with insomnia; and lastly, increased full body metabolism and heart rate in those with insomnia. All these findings taken together suggest a deregulation of the arousal system, cognitive system, and HPA axis, all contributing to insomnia.[9][77] However, it is unknown if the hyperarousal is a result of, or cause of insomnia. Altered levels of the inhibitory neurotransmitter GABA have been found, but the results have been inconsistent, and the implications of altered levels of such a ubiquitous neurotransmitter are unknown. Studies on whether insomnia is driven by circadian control over sleep or a wake-dependent process have shown inconsistent results, but some literature suggests a deregulation of the circadian rhythm based on core temperature.[78] Increased beta activity and decreased delta wave activity has been observed on electroencephalograms; however, the implication of this is unknown.[79]

Around half of post-menopausal women experience sleep disturbances, and generally, sleep disturbance is about twice as common in women as men; this appears to be due in part, but not completely, to changes in hormone levels, especially in post-menopause.[49][80]

Changes in sex hormones in both men and women as they age may account in part for an increased prevalence of sleep disorders in older people.[81]

Diagnosis

[edit]

In medicine, insomnia is measured using the Athens insomnia scale (AIS).[82] It measures eight parameters related to sleep, represented as an overall scale which assesses an individual's sleep quality. It has excellent internal consistency and re-test reliability.[83] The Athens Insomnia Scale for Non-Clinical Populations (AIS-NCA) has been developed and validated in English,[84] Chinese,[85] and German[84] to identify subclinical manifestations of insomnia in a language simpler than the Athens Insomnia Scale and more suitable for self-report. It uses four items to assess sleep problems and three items to assess impaired daytime functioning.

A medical history and a physical examination can identify other conditions that could be the cause of insomnia. A comprehensive sleep history should include sleep habits and sleep environment, medications (prescription and non-prescription, including supplements), alcohol, nicotine, and caffeine intake, and co-morbid illnesses.[86] A sleep diary can be used to track time to bed, total sleep time, time to sleep onset, number of awakenings, use of medications, time of awakening, and subjective feelings in the morning.[86] The sleep diary can be replaced or validated by the use of out-patient actigraphy for a week or more, using a non-invasive device that measures movement.[87]

Not everyone who suffers from insomnia should routinely have a polysomnography study to screen for sleep disorders,[88] but it may be indicated for those with risk factors for sleep apnea, including obesity, a thick neck diameter, or fullness of the flesh in the oropharynx.[88] For most people, the test is not needed to make a diagnosis, and insomnia can often be treated by changing their schedule to make time for sufficient sleep and by improving sleep hygiene.[88]

Some patients may need an overnight sleep study in a sleep lab. Such a study will commonly involve assessment tools including a polysomnogram and the multiple sleep latency test. Specialists in sleep medicine are qualified to diagnose disorders according to the ICSD, 81 major sleep disorder diagnostic categories.[89] Patients with some disorders, including delayed sleep phase disorder, are often misdiagnosed with primary insomnia; when a person has trouble getting to sleep and awakening at desired times, but has a normal sleep pattern once asleep, a circadian rhythm disorder is a likely cause.

In many cases, insomnia is co-morbid with another disease, side effects from medications, or a psychological problem. Approximately half of all diagnosed insomnia is related to psychiatric disorders.[90] For those who have depression, "insomnia should be regarded as a co-morbid condition, rather than as a secondary one;" insomnia typically predates psychiatric symptoms.[90] "In fact, it is possible that insomnia represents a significant risk for the development of a subsequent psychiatric disorder."[9] Insomnia occurs in between 60% and 80% of people with depression and can be a side effect of medications that treat depression.[91]

The determination of causation is not necessary for a diagnosis.[90]

DSM-5 criteria

[edit]

The DSM-5 criteria for insomnia include the following:[92]

"Predominant complaint of dissatisfaction with sleep quantity or quality, associated with one (or more) of the following symptoms":

  • Difficulty initiating sleep. (In children, this may manifest as difficulty initiating sleep without caregiver intervention.)
  • Difficulty maintaining sleep, characterized by frequent awakenings or problems returning to sleep after awakenings. (In children, this may manifest as difficulty returning to sleep without caregiver intervention.)
  • Early-morning awakening with inability to return to sleep.

In addition:

  • The sleep disturbance causes clinically significant distress or impairment in social, occupational, educational, academic, behavioral, or other important areas of functioning.
  • The sleep difficulty occurs at least three nights per week.
  • The sleep difficulty has been present for at least three months.
  • The sleep difficulty occurs despite adequate opportunity for sleep.
  • The insomnia is not better explained by and does not occur exclusively during another sleep-wake disorder (e.g., narcolepsy, a breathing-related sleep disorder, a circadian rhythm sleep-wake disorder, a parasomnia).
  • The insomnia is not attributable to the physiological effects of a substance (e.g., a drug of abuse, a medication)."

The DSM-IV TR includes insomnia but does not fully elaborate on the symptoms compared to the DSM-5. Instead of early-morning waking as a symptom, the DSM-IV-TR listed "nonrestorative sleep" as a primary symptom. The duration of the experience was also vague in the DSM-IV-TR. The DSM-IV-TR stated that symptoms had to be present for a month, whereas the DSM-5 states that symptoms must be present for three months and occur at least three nights a week (Gillette).

Types

[edit]

Insomnia can be classified as transient, acute, or chronic.

  • Transient insomnia lasts for less than a week. It can be caused by another disorder, by changes in the sleep environment, by the timing of sleep, severe depression, or by stress. Its consequences – sleepiness and impaired psychomotor performance – are similar to those of sleep deprivation.[93]
  • Acute insomnia is the inability to consistently sleep well for less than a month. Insomnia is present when there is difficulty initiating or maintaining sleep or when the sleep that is obtained is non-refreshing or of poor quality. These problems occur despite adequate opportunity and circumstances for sleep, and they must result in problems with daytime function.[94] Hyperarousal can be linked to acute insomnia since it activates the body's fight-or-flight response. When we encounter stress or danger, our bodies naturally become more alert, which can interfere with our capacity to both fall asleep and remain asleep. This heightened state of arousal can be useful in the short term during threatening situations, but if it continues over an extended period, it can result in acute insomnia.[95] Acute insomnia is also known as short term insomnia or stress related insomnia.[96]
  • Chronic insomnia lasts for longer than a month. It can be caused by another disorder, or it can be a primary disorder. Common causes of chronic insomnia include persistent stress, trauma, work schedules, poor sleep habits, medications, and other mental health disorders.[97] When an individual consistently engages in behaviors that disrupt their sleep, such as irregular sleep schedules, spending excessive time awake in bed, or engaging in stimulating activities close to bedtime, it can lead to conditioned wakefulness contributing to chronic insomnia.[95] People with high levels of stress hormones or shifts in the levels of cytokines are more likely than others to have chronic insomnia.[98] Its effects can vary according to its causes. They might include muscular weariness, hallucinations, and/or mental fatigue.[93]

Prevention

[edit]

Prevention and treatment of insomnia may require a combination of cognitive behavioral therapy,[13] medications,[99] and lifestyle changes.[100]

Among lifestyle practices, going to sleep and waking up at the same time each day can create a steady pattern which may help to prevent insomnia.[11] Avoidance of vigorous exercise and caffeinated drinks a few hours before going to sleep is recommended, while exercise earlier in the day may be beneficial.[100] Other practices to improve sleep hygiene may include:[100][101]

  • Avoiding or limiting naps
  • Treating pain at bedtime
  • Avoiding large meals, beverages, alcohol, and nicotine before bedtime
  • Finding soothing ways to relax into sleep, including the use of white noise
  • Making the bedroom suitable for sleep by keeping it dark, cool, and free of devices, such as clocks, cell phones, or televisions
  • Maintain regular exercise
  • Try relaxing activities before sleeping

Management

[edit]

It is recommended to rule out medical and psychological causes before deciding on the treatment for insomnia.[102] Cognitive behavioral therapy is an effective first-line treatment for chronic insomnia.[103][13] The beneficial effects, in contrast to those produced by medications, may last well beyond the stopping of therapy.[104]

Medications have been used mainly to reduce symptoms in insomnia of short duration; their role in the management of chronic insomnia remains unclear.[8] Several different types of medications may be used.[105][106][99] Many doctors do not recommend relying on prescription sleeping pills for long-term use.[100] These medications are not recommended for more than four or five weeks, although they can be used longer in certain instances.[6][15] It is also important to identify and treat other medical conditions that may be contributing to insomnia, such as depression, breathing problems, and chronic pain.[100][107] As of 2022, many people with insomnia were reported as not receiving overall sufficient sleep or treatment for insomnia.[108][109]

Non-medication based

[edit]

Non-medication-based strategies have comparable efficacy to hypnotic medication for insomnia, and they may have longer-lasting effects. Hypnotic medication is only recommended for short-term use because dependence with rebound withdrawal effects upon discontinuation or tolerance can develop.[110]

Non-medication-based strategies provide long-lasting improvements to insomnia and are recommended as a first-line and long-term strategy of management. Behavioral sleep medicine offers non-medication strategies to address chronic insomnia including sleep hygiene, stimulus control, behavioral interventions, sleep-restriction therapy, paradoxical intention, patient education, and relaxation therapy.[111] Some examples are keeping a journal, restricting the time spent awake in bed, practicing relaxation techniques, and maintaining a regular sleep schedule and a wake-up time. Behavioral therapy can assist a patient in developing new sleep behaviors to improve sleep quality and consolidation. Behavioral therapy may include learning healthy sleep habits to promote sleep relaxation, undergoing light therapy to regulate the circadian rhythm, and regulating the circadian clock.[107]

Music may improve insomnia in adults (see music and sleep).[112] EEG biofeedback has demonstrated effectiveness in the treatment of insomnia with improvements in duration as well as the quality of sleep.[113] Self-help therapy (defined as a psychological therapy that can be worked through on one's own) may improve sleep quality for adults with insomnia to a small or moderate degree.[114]

Stimulus control therapy is a treatment for patients who have conditioned themselves to associate the bed or sleep in general with a negative response. As stimulus control therapy involves taking steps to control the sleep environment, it is sometimes referred to interchangeably with the concept of sleep hygiene. Examples of such environmental modifications include using the bed for sleep and sex only, not for activities such as reading or watching television; waking up at the same time every morning, including on weekends; going to bed only when sleepy and when there is a high likelihood that sleep will occur; leaving the bed and beginning an activity in another location if sleep does not occur in a reasonably brief period after getting into bed (commonly ~20 min); reducing the subjective effort and energy expended trying to fall asleep; avoiding exposure to bright light during night-time hours, and eliminating daytime naps.[115]

A component of stimulus control therapy is sleep restriction, a technique that aims to match the time spent in bed with the actual time spent asleep. This technique involves maintaining a strict sleep-wake schedule, sleeping only at certain times of the day and for specific amounts of time to induce mild sleep deprivation. Complete treatment usually lasts up to 3 weeks and involves making oneself sleep for only a minimum amount of time that they are actually capable of on average, and then, if capable (i.e. when sleep efficiency improves), slowly increasing this amount (~15 min) by going to bed earlier as the body attempts to reset its internal sleep clock. Bright light therapy may be effective for insomnia.[116]

Paradoxical intention is a cognitive reframing technique where the insomniac, instead of attempting to fall asleep at night, makes every effort to stay awake (i.e., essentially stops trying to fall asleep). One theory that may explain the effectiveness of this method is that by not voluntarily making oneself go to sleep, it relieves the performance anxiety that arises from the need or requirement to fall asleep, which is meant to be a passive act. This technique has been shown to reduce sleep effort and performance anxiety and also lower subjective assessment of sleep-onset latency and overestimation of the sleep deficit (a quality found in many insomniacs).[117]

Sleep Hygiene

[edit]

Sleep hygiene is a common term for all of the behaviors that relate to the promotion of good sleep. They include habits that provide a good foundation for sleep and help to prevent insomnia. However, sleep hygiene alone may not be adequate to address chronic insomnia. Sleep hygiene recommendations are typically included as one component of cognitive behavioral therapy for insomnia (CBT-I).[87][6] Recommendations include reducing caffeine, nicotine, and alcohol consumption, maximizing the regularity and efficiency of sleep episodes, minimizing medication usage and daytime napping, the promotion of regular exercise, and the facilitation of a positive sleep environment.[118] The creation of a positive sleep environment may also help reduce the symptoms of insomnia.[119] On the other hand, a systematic review by the AASM concluded that clinicians should not prescribe sleep hygiene for insomnia due to the evidence of absence of its efficacy and potential delaying of adequate treatment, recommending instead that effective therapies such as CBT-i should be preferred.[14]

Cognitive behavioral therapy

[edit]

There is some evidence that cognitive behavioral therapy for insomnia (CBT-I) is superior not only in the long-term, but also in the short-term (2 months) to benzodiazepines and the nonbenzodiazepines in the treatment and management of insomnia.[120][121] In this therapy, patients are taught improved sleep habits and relieved of counter-productive assumptions about sleep. Common misconceptions and expectations that can be modified include:[citation needed]

  • Unrealistic sleep expectations.
  • Misconceptions about insomnia causes.
  • Amplifying the consequences of insomnia.
  • Performance anxiety after trying for so long to have a good night's sleep by controlling the sleep process.

Numerous studies have reported positive outcomes of combining cognitive behavioral therapy for insomnia treatment with treatments such as stimulus control and relaxation therapies. Hypnotic medications are equally effective in the short-term treatment of insomnia, but their effects wear off over time due to tolerance. The effects of CBT-I have sustained and lasting effects on treating insomnia long after therapy has been discontinued.[122][123] The addition of hypnotic medications with CBT-I adds no benefit in insomnia. The long-lasting benefits of a course of CBT-I shows superiority over pharmacological hypnotic drugs. Even in the short term, when compared to short-term hypnotic medication such as zolpidem, CBT-I still shows significant superiority. Thus, CBT-I is recommended as a first-line treatment for insomnia.[124]

Common forms of CBT-I treatments include stimulus control therapy, sleep restriction, sleep hygiene, improved sleeping environments, relaxation training, paradoxical intention, and biofeedback.[125] Sleep restriction (also called "time-in-bed restriction"), stimulus control and cognitive restructuring are key components[126].

CBT is a well-accepted form of therapy for insomnia since it has no known adverse effects, whereas taking medications to alleviate insomnia symptoms has been shown to have adverse side effects.[127] Nevertheless, the downside of CBT is that it may take a lot of time and motivation.[128]

Acceptance and commitment therapy

[edit]

Treatments based on the principles of acceptance and commitment therapy (ACT) and metacognition have emerged as alternative approaches to treating insomnia.[129] ACT rejects the idea that behavioral changes can help insomniacs achieve better sleep since they require "sleep efforts" - actions which create more "struggle" and arouse the nervous system, leading to hyperarousal.[130] The ACT approach posits that acceptance of the negative feelings associated with insomnia can, in time, create the right conditions for sleep. Mindfulness practice is a key feature of this approach, although mindfulness is not practiced to induce sleep (this in itself is a sleep effort to be avoided) but rather as a longer-term activity to help calm the nervous system and create the internal conditions from which sleep can emerge.

A key distinction between CBT-I and ACT lies in the divergent approaches to time spent awake in bed. Proponents of CBT-i advocate minimizing time spent awake in bed, on the basis that this creates a cognitive association between being in bed and wakefulness. The ACT approach proposes that avoiding time in bed may increase the pressure to sleep and arouse the nervous system further.[130]

Research has shown that "ACT has a significant effect on primary and comorbid insomnia and sleep quality, and ... can be used as an appropriate treatment method to control and improve insomnia".[131]

Internet Interventions

[edit]

Despite the therapeutic effectiveness and proven success of CBT, treatment availability is significantly limited by a lack of trained clinicians, poor geographical distribution of knowledgeable professionals, and expense.[132] One way to potentially overcome these barriers is to use the Internet to deliver treatment, making this effective intervention more accessible and less costly. The Internet has already become a critical source of health care and medical information.[133] Although the vast majority of health websites provide general information,[133][134] there is growing research literature on the development and evaluation of Internet interventions.[135][136]

These online programs are typically behaviorally based treatments that have been operationalized and transformed for delivery via the Internet. They are usually highly structured, automated, or human-supported, based on effective face-to-face treatment; personalized to the user; interactive; enhanced by graphics, animations, audio, and possibly video; and tailored to provide follow-up and feedback.[136]

There is good evidence for the use of computer-based CBT for insomnia.[137]

Medications

[edit]

Many people with insomnia use sleeping tablets and other sedatives. In some places, medications are prescribed in over 95% of cases.[138] They, however, are a second line treatment.[139] In 2019, the US Food and Drug Administration stated it is going to require warnings for eszopiclone, zaleplon, and zolpidem, due to concerns about serious injuries resulting from abnormal sleep behaviors, including sleepwalking or driving a vehicle while asleep.[140]

The percentage of adults using a prescription sleep aid increases with age. During 2005–2010, about 4% of U.S. adults aged 20 and over reported that they took prescription sleep aids in the past 30 days. Rates of use were lowest among the youngest age group (those aged 20–39) at about 2%, increased to 6% among those aged 50–59, and reached 7% among those aged 80 and over. More adult women (5%) reported using prescription sleep aids than adult men (3%). Non-Hispanic white adults reported higher use of sleep aids (5%) than non-Hispanic black (3%) and Mexican-American (2%) adults. No difference was shown between non-Hispanic black adults and Mexican-American adults in use of prescription sleep aids.[141]

Antihistamines

[edit]

As an alternative to taking prescription drugs, some evidence shows that an average person seeking short-term help may find relief by taking over-the-counter antihistamines such as diphenhydramine or doxylamine.[142] Diphenhydramine and doxylamine are widely used in nonprescription sleep aids. They are the most effective over-the-counter sedatives currently available, at least in much of Europe, Canada, Australia, and the United States, and are more sedating than some prescription hypnotics.[143] Antihistamine effectiveness for sleep may decrease over time, and anticholinergic side-effects (such as dry mouth) may also be a drawback with these particular drugs. While addiction does not seem to be an issue with this class of drugs, they can induce dependence and rebound effects upon abrupt cessation of use.[144] However, people whose insomnia is caused by restless legs syndrome may have worsened symptoms with antihistamines.[145]

Antidepressants

[edit]

While insomnia is a common symptom of depression, antidepressants are effective for treating sleep problems whether or not they are associated with depression. While all antidepressants help regulate sleep, some antidepressants, such as amitriptyline, doxepin, mirtazapine, trazodone, and trimipramine, can have an immediate sedative effect and are prescribed to treat insomnia.[146] Trazodone was at the beginning of the 2020s the most prescribed drug for sleep in the United States despite not being indicated for sleep.[147]

Amitriptyline, doxepin, and trimipramine all have antihistaminergic, anticholinergic, antiadrenergic, and antiserotonergic properties, which contribute to both their therapeutic effects and side effect profiles, while mirtazapine's actions are primarily antihistaminergic and antiserotonergic and trazodone's effects are primarily antiadrenergic and antiserotonergic. Mirtazapine is known to decrease sleep latency (i.e., the time it takes to fall asleep), promoting sleep efficiency and increasing the total amount of sleeping time in people with both depression and insomnia.[148][149]

Agomelatine, a melatonergic antidepressant with claimed sleep-improving qualities that does not cause daytime drowsiness,[150] is approved for the treatment of depression though not sleep conditions in the European Union[151] and Australia.[152] After trials in the United States, its development for use there was discontinued in October 2011[153] by Novartis, who had bought the rights to market it there from the European pharmaceutical company Servier.[154]

A 2018 Cochrane review found the safety of taking antidepressants for insomnia to be uncertain with no evidence supporting long term use.[155]

Melatonin agonists

[edit]

Melatonin receptor agonists such as melatonin and ramelteon are used in the treatment of insomnia. Prolonged-release melatonin improves insomnia mainly in adults ≥55, and ramelteon improves sleep generally, with both effective versus placebo but less effective than most licensed insomnia drugs and showing limited long-term benefits.[16][156][157][158]

The usage of melatonin as a treatment for insomnia in adults has increased from 0.4% between 1999 and 2000 to nearly 2.1% between 2017 and 2018.[159]

While the use of melatonin in the short term has been proven to be generally safe and is shown not to be a dependent medication, side effects can still occur.[160]

Most common side effects of melatonin include:[160]

  • Headache
  • Dizziness
  • Nausea
  • Daytime drowsiness

Studies have also shown that children who have an autism spectrum disorder or a learning disability, such as attention-deficit hyperactivity disorder (ADHD) or related neurological diseases, can benefit from the use of melatonin. This is because they often have trouble sleeping due to their disorders. For example, children with ADHD tend to have trouble falling asleep because of their hyperactivity and, as a result, tend to be tired during most of the day. Another cause of insomnia in children with ADHD is the use of stimulants to treat their disorder. Children who have ADHD, as well as the other disorders mentioned, may be given melatonin before bedtime to help them sleep.[161]

Benzodiazepines

[edit]
Normison (temazepam) is a benzodiazepine commonly prescribed for insomnia and other sleep disorders.[162]

The most commonly used class of hypnotics for insomnia are the benzodiazepines.[51]: 363  Benzodiazepines are not significantly better for insomnia than antidepressants.[163] Chronic users of hypnotic medications for insomnia do not have better sleep than chronic insomniacs not taking medications. In fact, chronic users of hypnotic medications have more regular night-time awakenings than insomniacs not taking hypnotic medications.[164] Many have concluded that these drugs cause an unjustifiable risk to the individual and to public health and lack evidence of long-term effectiveness. It is preferred that hypnotics be prescribed for only a few days at the lowest effective dose and avoided altogether wherever possible, especially in the elderly.[165] Between 1993 and 2010, the prescribing of benzodiazepines to individuals with sleep disorders has decreased from 24% to 11% in the US, coinciding with the first release of nonbenzodiazepines.[166]

The benzodiazepine and nonbenzodiazepine hypnotic medications also have several side effects, such as daytime fatigue, motor vehicle crashes and other accidents, cognitive impairments, and falls and fractures. Elderly people are more sensitive to these side effects.[167] Some benzodiazepines have demonstrated effectiveness in sleep maintenance in the short term but in the longer term benzodiazepines can lead to tolerance, physical dependence, benzodiazepine withdrawal syndrome upon discontinuation, and long-term worsening of sleep, especially after consistent usage over long periods. Benzodiazepines, while inducing unconsciousness, actually worsen sleep as – like alcohol – they promote light sleep while decreasing time spent in deep sleep.[168] A further problem is, with regular use of short-acting sleep aids for insomnia, daytime rebound anxiety can emerge.[169] Although there is little evidence for benefit of benzodiazepines in insomnia compared to other treatments and evidence of major harm, prescriptions have continued to increase.[170] This is likely due to their addictive nature, both due to misuse and because – through their rapid action, tolerance and withdrawal they can "trick" insomniacs into thinking they are helping with sleep. There is a general awareness that long-term use of benzodiazepines for insomnia in most people is inappropriate and that a gradual withdrawal is usually beneficial due to the adverse effects associated with the long-term use of benzodiazepines and is recommended whenever possible.[171][172]

Benzodiazepines all bind unselectively to the GABAA receptor.[163] Some theorize that certain benzodiazepines (hypnotic benzodiazepines) have significantly higher activity at the α1 subunit of the GABAA receptor compared to other benzodiazepines (for example, triazolam and temazepam have significantly higher activity at the α1 subunit compared to alprazolam and diazepam, making them superior sedative-hypnotics – alprazolam and diazepam, in turn, have higher activity at the α2 subunit compared to triazolam and temazepam, making them superior anxiolytic agents). Modulation of the α1 subunit is associated with sedation, motor impairment, respiratory depression, amnesia, ataxia, and reinforcing behavior (drug-seeking behavior). Modulation of the α2 subunit is associated with anxiolytic activity and disinhibition. For this reason, certain benzodiazepines may be better suited to treat insomnia than others.[119]

Z-Drugs

[edit]

Nonbenzodiazepine or Z-drug sedative–hypnotic drugs, such as zolpidem, zaleplon, zopiclone, and eszopiclone, are a class of hypnotic medications that are similar to benzodiazepines in their mechanism of action, and indicated for mild to moderate insomnia. Their effectiveness at improving time to sleeping is slight, and they have similar—though potentially less severe—side effect profiles compared to benzodiazepines.[173] Prescribing of nonbenzodiazepines has seen a general increase since their initial release on the US market in 1992, from 2.3% in 1993 among individuals with sleep disorders to 13.7% in 2010.[166]

Orexin antagonists

[edit]

Orexin receptor antagonists are a more recently introduced class of sleep medications and include suvorexant, lemborexant, and daridorexant, all of which are FDA-approved for treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.[174][175] They are oriented towards blocking signals in the brain that stimulate wakefulness, therefore claiming to address insomnia without creating dependence. There are three dual orexin receptor (DORA) drugs on the market: Belsomra (Merck), Dayvigo (Eisai) and Quviviq (Idorsia).[147]

Antipsychotics

[edit]

Certain atypical antipsychotics, particularly quetiapine, olanzapine, and risperidone, are used in the treatment of insomnia.[176][177] However, while common, the use of antipsychotics for this indication is not recommended as the evidence does not demonstrate a benefit, and the risk of adverse effects is significant.[176][178][179][180] A major 2022 systematic review and network meta-analysis of medications for insomnia in adults found that quetiapine did not demonstrate any short-term benefits for insomnia.[16] Some of the more serious adverse effects may also occur at the low doses used, such as dyslipidemia and neutropenia.[181][182] Such concerns of risks at low doses are supported by Danish observational studies that showed an association of use of low-dose quetiapine (excluding prescriptions filled for tablet strengths >50 mg) with an increased risk of major cardiovascular events as compared to use of Z-drugs, with most of the risk being driven by cardiovascular death.[183] Laboratory data from an unpublished analysis of the same cohort also support the lack of dose-dependency of metabolic side effects, as new use of low-dose quetiapine was associated with a risk of increased fasting triglycerides at one-year follow-up.[184] Concerns regarding side effects are greater in the elderly.[185]

Other sedatives

[edit]

Gabapentinoids like gabapentin and pregabalin have sleep-promoting effects, but are not commonly used for the treatment of insomnia.[186] Gabapentin is not effective in helping alcohol related insomnia.[187][188]

Barbiturates, while once used, are no longer recommended for insomnia due to the risk of addiction and other side effects.[189]

Comparative effectiveness

[edit]

Medications for the treatment of insomnia have a wide range of effect sizes.[16] When comparing drugs such as benzodiazepines, Z-drugs, sedative antidepressants and antihistamines, quetiapine, orexin receptor antagonists, and melatonin receptor agonists, the orexin antagonist lemborexant and the Z-drug eszopiclone had the best profiles overall in terms of efficacy, tolerability, and acceptability.[16]

Alternative medicine

[edit]

Herbal products, such as valerian, kava, chamomile, and lavender, have been used to treat insomnia.[15][190][191] However, there is no quality evidence that they are effective and safe.[15][190][191] The same is true for cannabis and cannabinoids.[192][193][194] It is likewise unclear whether acupuncture is useful in the treatment of insomnia.[195]

Prognosis

[edit]
Disability-adjusted life year for insomnia per 100,000 inhabitants in 2004:
  no data
  less than 25
  25–30.25
  30.25–36
  36–41.5
  41.5–47
  47–52.5
  52.5–58
  58–63.5
  63.5–69
  69–74.5
  74.5–80
  more than 80

A survey of 1.1 million residents in the United States found that those who reported sleeping about 7 hours per night had the lowest rates of mortality, whereas those who slept for fewer than 6 hours or more than 8 hours had higher mortality rates. Severe insomnia—sleeping less than 3.5 hours in women and 4.5 hours in men—is associated with a 15% increase in mortality, while getting 8.5 or more hours of sleep per night was associated with a 15% higher mortality rate.[196]

With this technique, it is difficult to distinguish the lack of sleep caused by a disorder, which is also a cause of premature death, versus a disorder that causes a lack of sleep, and the lack of sleep, causing premature death. Most of the increase in mortality from severe insomnia was discounted after controlling for associated disorders. After controlling for sleep duration and insomnia, the use of sleeping pills was also found to be associated with an increased mortality rate.[196]

The lowest mortality was seen in individuals who slept between six and a half and seven and a half hours nightly. Even sleeping only 4.5 hours per night is associated with a very small increase in mortality. Thus, mild to moderate insomnia for most people is associated with increased longevity, and severe insomnia is associated only with a very small effect on mortality.[196] It is unclear why sleeping longer than 7.5 hours is associated with excess mortality.[196]

Epidemiology

[edit]

Between 10% and 30% of adults have insomnia at any given point in time and up to half of people have insomnia in a given year, making it the most common sleep disorder.[9][8][10][197] About 6% of people have insomnia that is not due to another problem and lasts for more than a month.[9] People over the age of 65 are affected more often than younger people.[7] Females are more often affected than males.[8] Insomnia is 40% more common in women than in men.[198]

There are higher rates of insomnia reported among university students compared to the general population.[199]

Society and culture

[edit]

The word insomnia is from Latin: in + somnus "without sleep" and -ia as a nominalizing suffix.

The popular press have published stories about people who supposedly never sleep, such as that of Thái Ngọc and Al Herpin.[200] Horne writes "everybody sleeps and needs to do so", and generally this appears true. However, he also relates from contemporary accounts the case of Paul Kern, who was shot in 1915 fighting in World War I and then "never slept again" until he died in 1955.[201] Kern appears to be a completely isolated, unique case.

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia
from Grokipedia
Insomnia is a prevalent characterized by persistent difficulty falling asleep, staying asleep, or experiencing nonrestorative , despite having adequate opportunity and environmental conditions for , often resulting in daytime impairments such as , impaired concentration, or mood disturbances. It manifests in two primary forms: acute insomnia, which is short-term and typically lasts from a few days to several weeks, often triggered by temporary stressors like life events or ; and chronic insomnia, defined as occurring at least three nights per week for three months or longer, which may persist independently or alongside other conditions. Prevalence estimates indicate that approximately 30% of adults report insomnia symptoms, with about 10% experiencing significant daytime consequences, and rates are higher among women, older adults, and those with comorbid medical or psychiatric disorders. Common nighttime symptoms include prolonged time to fall asleep, frequent awakenings, or early morning awakenings with inability to return to sleep, while daytime effects encompass excessive sleepiness, , reduced performance at work or , and increased of errors or accidents. These disruptions can exacerbate underlying issues, contributing to heightened risks for conditions such as , , and depression. Etiologically, insomnia arises from a combination of factors, including psychological stressors like anxiety or , physiological hyperarousal involving elevated levels, poor practices such as irregular schedules or consumption, and comorbidities including mental health disorders (e.g., depression affecting up to 40% of cases), , or other sleep disorders like . Treatment approaches emphasize non-pharmacological interventions as first-line options, such as , which addresses maladaptive thoughts and behaviors to improve sleep patterns, alongside education; medications like hypnotics may be used short-term for severe cases, but underlying causes must also be managed to prevent recurrence.

Signs and Symptoms

Sleep Disturbances

Insomnia is fundamentally characterized by disruptions in the nighttime process that persist despite sufficient opportunity for rest. The primary sleep disturbances include difficulty initiating , often quantified as a exceeding 30 minutes, where individuals struggle to fall asleep after retiring to bed. This prolonged latency reflects an inability to transition effectively into , distinguishing it from brief delays that may occur occasionally in healthy individuals. Maintenance of is another core issue, involving frequent during the night or prolonged periods of after sleep onset, typically greater than 30 minutes. Early morning , where individuals wake earlier than desired and cannot return to , further exacerbate this fragmentation, often resulting in total time below 6.5 hours. These interruptions lead to fragmented sleep architecture, with reduced sleep efficiency—defined as the percentage of time in bed spent asleep—falling below 85%. Non-restorative , characterized by a subjective sense of unrefreshing rest despite adequate duration, accompanies these problems but does not occur in isolation; it must coexist with or maintenance difficulties to meet diagnostic thresholds. These disturbances differ from normal sleep variability, which involves occasional nights of suboptimal sleep due to transient factors like stress or environmental changes, without the persistence or associated distress required for a disorder . In insomnia, the issues must occur at least three nights per week for a minimum of three months to signify a chronic pattern, rather than episodic fluctuations typical in the general population. This chronicity underscores the disorder's impact on overall sleep continuity, as measured by or sleep diaries in clinical settings.

Daytime Impairments

Insomnia leads to a range of daytime impairments that significantly affect cognitive, emotional, physical, and functional domains of daily life. These consequences arise from disrupted sleep continuity and quality, as detailed in prior discussions of sleep disturbances, and contribute to reduced overall . Research consistently shows that individuals with insomnia experience heightened vulnerability to these effects, which can persist even after apparent sleep recovery. Cognitive deficits are prominent among daytime impairments in insomnia, particularly affecting , , and . Studies indicate that people with insomnia exhibit reduced sustained and increased attentional lapses, leading to difficulties in maintaining focus on tasks. Memory impairments, including deficits in and episodic recall, have been observed through objective neuropsychological testing, with insomnia sufferers showing poorer performance compared to good sleepers. Decision-making processes are also compromised, as evidenced by heightened risk-taking and slower problem-solving in simulated scenarios, underscoring the impact on executive function. Emotional disturbances manifest as irritability, anxiety, and depressed mood, exacerbating the psychological burden of insomnia. Individuals often report elevated and emotional reactivity during waking hours, which correlates with poorer sleep efficiency. Anxiety symptoms, including heightened worry and physiological , are prevalent and linked to daytime dysfunction, with insomnia significantly increasing the risk of clinical anxiety. Depressed mood is similarly common, with chronic insomnia associated with symptoms such as low energy and persistent sadness, independent of primary mood disorders. Physical symptoms during the day include , headaches, and gastrointestinal issues, reflecting the systemic toll of sleep disruption. is a core complaint, characterized by persistent tiredness and reduced physical endurance, reported by the majority of insomnia patients. Headaches, often tension-type, occur frequently and may stem from heightened muscle tension or altered pain sensitivity. Gastrointestinal disturbances, such as abdominal discomfort or altered bowel habits, are linked to sleep deprivation's effects on gut and . Functional impacts extend to work performance, driving safety, and social relationships, impairing overall productivity and interpersonal dynamics. At work, insomnia reduces performance through errors, absenteeism, and lower output, with affected individuals engaging in fewer safety behaviors. Driving safety is compromised, as insomnia elevates crash risk via impaired vigilance and reaction times during monotonous tasks. Socially, it strains relationships by fostering conflicts and reducing empathy, leading to isolation and diminished quality of life. The Insomnia Severity Index (ISI) is a validated tool for assessing daytime complaints, with items specifically targeting functional impairments like satisfaction with and daytime interference. Scores on these items help quantify the severity of cognitive, emotional, and physical effects, guiding clinical evaluation.

Behavioral Indicators

Individuals with insomnia often exhibit maladaptive behaviors that perpetuate sleep difficulties by interfering with natural sleep processes. One prominent indicator is excessive time spent in bed without achieving sleep, known as prolongation, where individuals extend their time in bed in an attempt to compensate for lost sleep, but this reduces sleep drive and efficiency, leading to prolonged wakefulness after sleep onset. According to the 3P model of insomnia, such behaviors maintain the disorder by disrupting homeostatic sleep regulation. Irregular sleep schedules and excessive napping further exacerbate insomnia by desynchronizing the circadian rhythm and diminishing the pressure to sleep at night. People may shift bedtimes erratically or nap during the day to alleviate daytime fatigue, which fragments nighttime sleep and reinforces the cycle of poor sleep quality. These patterns are common perpetuating factors identified in behavioral models of insomnia. Worry about can lead to conditioned , where anxiety over not sleeping becomes associated with the environment, triggering physiological hyperarousal upon entering . This conditioned response, characterized by increased and cognitive rumination, hinders initiation and is a core feature of psychophysiological insomnia. Research shows that such worry strengthens sleep-interfering associations over time. Avoidance of sleep-related activities due to of failure manifests as safety behaviors, such as delaying or leaving the if does not come quickly, aimed at preventing the distress of perceived sleep failure. These strategies, while temporarily reducing anxiety, maintain insomnia by weakening the bed- association and promoting irregular habits. Studies indicate that such avoidance behaviors correlate with greater insomnia severity. The use of before bedtime plays a significant in delaying onset, as exposure to blue light from screens suppresses production and heightens cognitive arousal. Evening , particularly for more than one hour, has been linked to a 59% increased of insomnia symptoms and reduced duration by approximately 24 minutes per night.

Causes and Risk Factors

Predisposing Factors

Predisposing factors for insomnia encompass inherent vulnerabilities that heighten an individual's susceptibility to the disorder, including genetic, demographic, and physiological elements. Genetic influences play a significant , with twin studies estimating the of insomnia at 30-50%, indicating that genetic factors account for a substantial portion of the variance in insomnia . Family history further supports this, as individuals with a first-degree relative affected by insomnia exhibit elevated , corroborated by twin and studies demonstrating shared genetic liabilities beyond environmental influences. Specific genes, such as PER2, a core component of the , have been implicated through polymorphisms associated with disrupted regulation and increased insomnia vulnerability. Age-related changes represent another key predisposing factor, with insomnia prevalence peaking in older adults due to alterations in circadian rhythms, including phase advances that lead to earlier onset and awakenings. These shifts, often compounded by reduced production and fragmented sleep architecture, make elderly individuals more prone to chronic difficulties. Female sex confers a higher for insomnia, primarily attributed to hormonal fluctuations across the lifespan, such as those during menstrual cycles, , and particularly , where decline disrupts continuity in up to 40-60% of women. Chronic medical conditions also predispose individuals, with disorders like persistent pain syndromes (e.g., or ) and respiratory issues (e.g., or ) interfering with initiation and maintenance through discomfort and breathing difficulties. These comorbidities create a baseline vulnerability that amplifies insomnia development when combined with other stressors.

Precipitating Factors

Precipitating factors are acute events or conditions that initiate episodes of insomnia by disrupting normal sleep patterns, often leading to short-term sleep difficulties that may resolve or evolve further. These triggers can vary widely but commonly involve sudden changes in an individual's circumstances or physiology. Life stressors, such as job loss, bereavement, or trauma, frequently act as primary precipitants by heightening arousal and emotional distress, thereby interfering with sleep initiation and maintenance. This arousal frequently involves sympathetic nervous system activation from stress or anxiety, leading to a state where individuals feel sleepy but are unable to fall asleep due to persistent hyperarousal. For instance, work-related events like job loss and family issues including bereavement were identified as the most common triggers in a study of insomnia patients, with 65% of such events carrying a negative emotional valence. Trauma exposure, particularly in contexts like posttraumatic stress, has been shown to directly contribute to the onset of insomnia through hyperarousal mechanisms following the event. Substance-induced triggers encompass the acute effects of , alcohol, , and certain medications, which can alter architecture and promote wakefulness. blocks receptors, delaying onset when consumed later in the day, while alcohol initially sedates but fragments in the second half of the night. , as a , increases sleep latency and reduces total time, and medications like stimulants or beta-blockers can exacerbate insomnia by interfering with circadian rhythms or causing side effects such as nightmares or restlessness. Environmental disruptions, including excessive noise, light exposure, or irregular work schedules like , precipitate insomnia by desynchronizing the body's internal clock or creating an unsuitable setting. , for example, forces during daylight hours, leading to reduced efficiency due to circadian misalignment. Similarly, sudden changes in ambient conditions, such as unfamiliar noise or light in a new environment, can acutely hinder consolidation. Recent highlights the role of digital devices and as modern precipitants, with evening exposure to blue light suppressing and social media use increasing anxiety, contributing to sleep onset difficulties, often manifesting as feeling sleepy but unable to fall asleep, as of 2024. Acute illnesses or pain episodes often trigger insomnia by causing discomfort or physiological arousal that overrides sleep drives. Conditions involving , such as acute injuries or infections, disrupt sleep through heightened sensory input and , with studies noting their role in initiating sleep disturbances alongside other health burdens like dyspnea. Jet lag and travel-related circadian misalignment precipitate insomnia by rapidly shifting the sleep-wake cycle across time zones, resulting in difficulty falling asleep at the destination's nighttime. This misalignment typically causes transient insomnia lasting days to weeks, depending on the number of zones crossed and direction of travel. In some cases, insomnia onset is sudden and severe without an immediately apparent precipitating factor. Such presentations are generally secondary to an underlying condition that is not readily evident. Common underlying causes include psychological disorders (such as anxiety, depression, or hidden stress), endocrine disorders (such as hyperthyroidism), side effects of medications (including corticosteroids and certain antidepressants), substance withdrawal, hormonal disorders (such as menopause), or other medical conditions (such as chronic pain or sleep apnea). In cases of sudden severe insomnia, medical consultation is essential to identify and address the underlying cause.

Perpetuating Factors

Perpetuating factors in insomnia refer to the ongoing psychological, behavioral, and physiological elements that sustain difficulties long after initial precipitating events have subsided, transforming transient sleep problems into a chronic disorder. Central to understanding these factors is the 3P model proposed by Spielman and colleagues, which delineates predisposing traits, precipitating triggers, and perpetuating mechanisms; specifically, perpetuating factors encompass maladaptive responses and habits that reinforce hyperarousal and disrupt continuity, preventing natural recovery. This model highlights how these elements create a self-sustaining cycle, where attempts to compensate for poor inadvertently exacerbate the problem. Maladaptive coping strategies, such as excessive about sleep loss or engaging in safety behaviors like clock-watching and repeated attempts to fall asleep, play a key role in maintaining insomnia by heightening cognitive and prolonging in bed. These behaviors often arise as individuals try to control their but instead amplify anxiety and , leading to a vicious cycle of rumination that interferes with onset and quality. For instance, safety behaviors like lying awake while monitoring the time can extend time in bed without improving sleep efficiency, further entrenching the disorder. Conditioned arousal represents another critical perpetuating factor, where the and environment become associated with and distress rather than rest, due to repeated experiences of struggling to . This process results in physiological and cognitive activation upon entering the sleep setting, even in the absence of immediate stressors, as the cues trigger hyper that inhibits sleep initiation. Over time, this association strengthens, making the bedroom a source of anxiety and perpetuating the insomnia independently of original causes. Poor practices, including irregular sleep-wake schedules, excessive napping, stimulating activities before bed, and lack of regular physical activity, reinforce the insomnia cycle by disrupting circadian rhythms and consolidating wakefulness during intended periods. These habits, often adopted in response to initial sleep difficulties, lead to fragmented sleep architecture and reduced drive, as prolonged time in bed dilutes the homeostatic pressure for without addressing underlying . Lack of physical activity can further perpetuate insomnia by decreasing the body's natural sleep pressure. Evidence indicates that such practices are particularly insidious in chronic cases, where they prevent the re-establishment of efficient patterns. Comorbid conditions, particularly anxiety disorders, sustain insomnia by maintaining a state of chronic hyperarousal that heightens physiological and emotional activation, making relaxation and attainment more challenging. In individuals with co-occurring anxiety, symptoms like persistent worry and autonomic overactivity perpetuate disturbances through shared neurobiological pathways, such as elevated hypothalamic-pituitary-adrenal axis activity, which delays onset and increases awakenings. This interplay underscores how untreated anxiety can transform episodic insomnia into a persistent condition, with studies showing bidirectional reinforcement between the two.

Pathophysiology

Neurobiological Mechanisms

Insomnia is fundamentally characterized by a state of hyper, encompassing heightened physiological, cognitive, and cortical activation that disrupts and . This posits that individuals with insomnia exhibit persistent overactivity across multiple levels, from molecular processes to whole-brain networks, preventing the necessary deactivation of arousal systems during attempts. Key physiological markers include elevated evening and nocturnal levels, reflecting dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, which sustains stress responses incompatible with . Sympathetic nervous system (SNS) activity is also enhanced, particularly during onset, as evidenced by reduced cardiac pre-ejection period values indicating greater adrenergic drive. Furthermore, insomnia patients display an increased 24-hour metabolic rate, measured via higher oxygen consumption, suggesting a basal hypermetabolic state that undermines needed for . Neurotransmitter imbalances contribute significantly to this hyperarousal. Gamma-aminobutyric acid (GABA), the primary inhibitory , shows inconsistent but often reduced levels in key regions such as the occipital cortex and anterior cingulate, impairing inhibition of excitatory signals and promoting wakefulness. Serotonin dysregulation, particularly the short allele of the gene, is associated with altered mood and arousal regulation, exacerbating sleep disturbances in susceptible individuals. (hypocretin), a wake-promoting from the , exhibits elevated nocturnal activity in insomnia, stabilizing excessive wakefulness and disrupting the sleep-wake transition; this is targeted therapeutically by antagonists like . Brain imaging studies reveal increased activity in hyperarousal networks, supporting the physiological evidence. Functional MRI findings indicate heightened functional connectivity between the —a noradrenergic nucleus critical for —and regions like the and insula, correlating with subjective sleep quality impairments. during sleep onset shows elevated beta activity in frontal regions, reflecting cortical hyperarousal, while structural MRI reveals reduced gray matter volume in prefrontal areas involved in executive control and emotion regulation. Circadian rhythm disruptions further perpetuate insomnia's neurobiological underpinnings. secretion, which signals readiness, is diminished in the evening and exhibits phase delays in patients with sleep-onset difficulties, misaligning the internal clock with desired times. Core body rhythms are similarly altered: maintenance insomnia links to nocturnally elevated temperatures that inhibit propensity, while onset and early awakening subtypes associate with delayed or advanced phase timings, respectively, disrupting the thermoregulatory drop essential for . The sleep-wake regulation process, modeled as a "flip-flop switch," involves mutual inhibition between arousal-promoting neurons (e.g., in the and systems) and sleep-promoting neurons in the , ensuring stable state transitions via and galanin-mediated suppression. In insomnia, this bistable mechanism is impaired, leading to chronic coactivation of wake and sleep circuits, state instability, and intrusions of wakefulness into sleep periods, as indicated by persistent brain hypermetabolism on .

Cognitive and Behavioral Models

Cognitive and behavioral models of insomnia emphasize the role of psychological processes in maintaining sleep difficulties, integrating predisposing vulnerabilities with perpetuating thought patterns and learned habits. The Spielman 3P model, originally delineating predisposing, precipitating, and perpetuating factors, has been extended to incorporate cognitive elements, where predisposing traits such as heighten vulnerability to sleep-related worries, while perpetuating factors involve maladaptive cognitions and behaviors that sustain . In this framework, cognitive aspects amplify the transition from acute to chronic insomnia by fostering heightened monitoring of and unhelpful safety behaviors, such as excessive planning for bedtime routines. Central to these models are cognitive distortions, including catastrophic thinking about sleep loss, where individuals overestimate the consequences of poor , such as impaired or decline, thereby intensifying anxiety and delaying sleep onset. This pattern aligns with Allison Harvey's of insomnia, which posits that such distortions contribute to a cycle of that perpetuates . For instance, beliefs like "I must get eight hours of or I will fail tomorrow" exemplify how these thoughts escalate pre-sleep arousal, distinguishing insomnia from other issues by their specificity to sleep-related threats. Behavioral conditioning further entrenches insomnia through learned associations between the bed and alertness, often termed conditioned arousal, where repeated experiences of in bed transform the environment into a cue for vigilance rather than rest. This process, highlighted in paradigms, leads individuals to avoid the during non-sleep times to re-associate it with , breaking the cycle of . Such conditioning is a key perpetuating factor in the 3P model, as irregular schedules reinforce the mismatch between sleep drive and environmental cues. Rumination on sleep failures and attentional bias toward sleep-related threats exacerbate these issues by directing focus to negative sleep cues, such as clock-watching or bodily sensations, which prolong cognitive and inhibit sleep initiation. In model, this maintains insomnia by amplifying threat perception, where neutral stimuli are interpreted as indicators of impending sleeplessness, supported by showing elevated rumination in insomnia patients compared to good sleepers. Studies indicate that this perseverative thinking extends daytime worries into the night, linking cognitive hyperarousal to prolonged latency. Evidence from studies utilizing cognitive scales underscores these mechanisms, with the Pre-Sleep Scale (PSAS) demonstrating higher cognitive subscale scores in individuals with insomnia, correlating with subjective quality and daytime impairment. Validation research on the PSAS reveals that cognitive items, such as about the day, predict insomnia severity more robustly than somatic factors, providing quantifiable support for targeted interventions. These findings affirm the interplay of cognitive and behavioral elements in sustaining insomnia, often intertwined with underlying physiological hyper.

Diagnosis

Clinical Assessment

Patients should seek professional help promptly if insomnia is sudden and severe without an apparent cause, as this presentation often indicates an underlying condition requiring immediate evaluation. Professional consultation is also recommended if self-help methods fail after 1-2 months and insomnia symptoms severely impact daily life, such as occurring multiple nights per week. Consultation with a sleep specialist, psychologist, or physician is advised to thoroughly evaluate for underlying conditions including psychological disorders (anxiety, depression, hidden stress), endocrine disorders (hyperthyroidism), medication side effects (corticosteroids, antidepressants, etc.), substance withdrawal, hormonal changes (menopause), or other medical conditions (chronic pain, obstructive sleep apnea, etc.). Cognitive behavioral therapy is preferred as the initial approach over sleeping pills. The clinical assessment of insomnia begins with a comprehensive evaluation to characterize the sleep complaint, its duration, severity, and impact on functioning, ensuring adequate opportunity is available despite the difficulties. This process typically involves gathering detailed patient history to identify patterns of initiation, maintenance, or early awakening, along with associated nocturnal behaviors and consequences such as or impaired concentration. Patient history taking is foundational and includes a thorough review of sleep-wake schedules, routines, environmental factors, and potential precipitating events like life stressors or travel. Clinicians often employ sleep diaries, where patients prospectively record , awakenings, total sleep time, and daytime naps over 1-2 weeks to provide objective insights into sleep patterns and variability. Standardized questionnaires further quantify sleep quality and severity; for instance, the (PSQI) assesses multiple dimensions of sleep over the past month, with scores above 5 indicating poor sleep quality.80047-4) A is conducted to detect signs of comorbidities that may contribute to or mimic insomnia, such as or enlarged neck circumference suggestive of , or features of dysfunction or conditions. This exam also includes a mental status evaluation to gauge alertness, mood, and cognitive function. If an organic cause is suspected after initial evaluation, blood tests may be ordered to assess thyroid hormones, iron or vitamin deficiencies (such as B12 or D), and blood sugar levels. is essential to distinguish insomnia from other sleep disorders, including (characterized by and ) or (with uncomfortable leg sensations prompting movement). It also rules out conditions like disorders or insufficient sleep syndrome, often requiring consideration of overlapping symptoms through targeted questioning. Objective measures are used selectively when history alone is inconclusive. Actigraphy, involving wrist-worn devices to monitor rest-activity cycles and enable home sleep tracking, is indicated for assessing circadian patterns or compliance in patients with suspected rhythm disruptions or comorbidities like depression. (PSG), an overnight laboratory study recording brain waves, breathing, heart rate, oxygen levels, and leg movements, is not routine but recommended if sleep-disordered breathing, , or treatment-refractory insomnia is suspected; wait times for such studies may vary. Rarely, an electroencephalogram (EEG) is ordered for evaluation of neurological issues. Screening for substance use and mental health issues is integrated throughout the assessment, as caffeine, alcohol, nicotine, or illicit drugs can exacerbate sleep fragmentation, while conditions like anxiety or depression often co-occur with insomnia in up to 50% of cases. Validated tools such as the or brief mental health screeners help identify these factors early.

Diagnostic Criteria and Types

Insomnia disorder is diagnosed based on standardized criteria outlined in major classification systems, primarily the , and the . These frameworks emphasize the presence of dissatisfaction leading to clinically significant distress or impairment, with specific thresholds for frequency, duration, and exclusion of alternative explanations. In the , the core diagnostic criteria for insomnia disorder require a predominant complaint of dissatisfaction with quantity or quality, manifested as difficulty initiating , maintaining (characterized by frequent awakenings or prolonged time to return to ), early-morning awakening with inability to return to , or nonrestorative . This disturbance must cause clinically significant distress or impairment in social, occupational, educational, or other key areas of functioning; occur at least three per week; persist for at least ; and arise despite adequate opportunity for . Additionally, the insomnia cannot be better explained by another sleep-wake disorder (such as , breathing-related sleep disorder, circadian rhythm sleep-wake disorder, or ), nor attributable to the physiological effects of a substance (e.g., drug abuse or ). Coexisting mental disorders or medical conditions do not preclude the if the insomnia complaint warrants independent clinical attention, though specifiers are used to note comorbidities like non-sleep disorder mental conditions, other medical issues, or other sleep disorders. The , implemented post-2019, aligns closely with but introduces refinements for chronicity and within its sleep-wake disorders chapter (6D). Insomnia disorders are defined by persistent difficulty with initiation, duration, consolidation, or quality, occurring at least three times per week for at least three months (chronic insomnia, code 6D51), causing significant distress or impairment in personal, family, social, educational, occupational, or other functioning, and persisting despite adequate opportunity and circumstances for . Short-term insomnia (code 6D50) follows similar features but lasts less than three months. As in , the condition must not be better explained by another sleep-wake disorder, , medical condition, substance use, or environmental factors. emphasizes a unified approach to insomnia regardless of comorbidities, without requiring causal attribution to other conditions. Insomnia is classified into types based on duration and presentation. Acute insomnia, also termed short-term or adjustment insomnia, involves symptoms lasting less than three months, often triggered by identifiable stressors, and resolves spontaneously or with intervention. Chronic insomnia persists for three months or longer, representing the more severe, enduring form that requires targeted and management. Subtypes are delineated by the primary sleep complaint: onset insomnia (difficulty falling asleep), maintenance insomnia (trouble staying asleep due to awakenings), early morning awakening (waking too early with inability to resume sleep), or mixed/nonrestorative types combining these features. Distinctions between primary and comorbid insomnia have evolved in modern criteria. Earlier systems like DSM-IV separated primary insomnia (independent of other conditions) from secondary forms linked to psychiatric, medical, or substance-related issues; however, and eliminate this dichotomy, diagnosing insomnia disorder as a standalone entity even when comorbid, provided it meets full criteria and merits separate attention. This shift recognizes insomnia's bidirectional relationships with comorbidities without implying . Exclusion criteria across both systems rule out hypersomnolence disorders (e.g., excessive daytime sleepiness without insomnia features) or parasomnias (e.g., abnormal behaviors during sleep like ), ensuring the diagnosis captures true insomnia phenomenology.

Prevention

Lifestyle Modifications

Maintaining a consistent sleep-wake is a foundational lifestyle modification for preventing insomnia, as it helps regulate the body's and promotes stable sleep patterns. Individuals are advised to go to bed and wake up at the same time every day, including weekends, to avoid disruptions from irregular shifts that can desynchronize internal clocks and increase insomnia risk. Optimizing the sleep environment plays a crucial role in fostering conditions conducive to restful and reducing the likelihood of insomnia onset. Bedrooms should be kept cool (ideally 16–20°C or 60–68°F), dark (using blackout curtains or eye masks to block light), and quiet (employing earplugs or white noise machines to minimize disturbances), as these factors directly influence sleep initiation and maintenance by minimizing sensory interruptions. Dietary adjustments can significantly mitigate insomnia risk by avoiding stimulants and digestive discomfort near . Limiting intake after noon is recommended, as its can extend up to 8 hours, potentially delaying onset and reducing quality; similarly, heavy or spicy meals should be avoided close to to prevent and that disrupt . Incorporating regular into daily routines supports insomnia prevention by enhancing overall quality, though timing is essential to avoid interference with . Moderate exercise, such as walking or aerobic activity for at least 30 minutes most days, promotes deeper stages, but vigorous sessions should be scheduled at least 4 hours before to allow body temperature and levels to normalize. Routine use of relaxation techniques, such as (PMR), can prevent insomnia by reducing pre-sleep tension and promoting a calm state conducive to . PMR involves systematically tensing and releasing muscle groups from toes to head, which has been shown to decrease anxiety and improve sleep efficiency when practiced nightly before bed. For those experiencing symptoms of anxiety and insomnia while awaiting medical consultation, auxiliary self-regulation measures include maintaining a regular sleep schedule with early bedtimes and wake-up times to avoid late nights; engaging in moderate exercise such as walking or yoga to relieve tension; consuming balanced meals rich in B vitamins and protein without forcing intake; and practicing deep breathing, meditation, or listening to light music for relaxation. These strategies support interim symptom management but are not substitutes for professional treatments.

Early Intervention Strategies

Early intervention strategies target high-risk individuals exposed to precipitating events or vulnerabilities, aiming to disrupt the progression from acute sleep disturbances to chronic insomnia through proactive, tailored approaches. These strategies emphasize timely identification and modifiable behaviors to preserve and prevent perpetuation. programs are essential for individuals facing precipitating events, such as , which disrupts circadian rhythms and heightens insomnia risk. (MBSR) has shown efficacy in reducing sleep-related worry and improving quality among shift workers by enhancing emotional regulation and decreasing cognitive arousal. For instance, trait correlates inversely with sleep disturbances in shift nurses, suggesting protective effects against insomnia onset. These programs typically involve 8-week structured sessions focusing on and body awareness to mitigate and unwanted nocturnal . Screening and education initiatives are critical for vulnerable populations, including the elderly and postpartum women, where predisposing factors like age-related circadian shifts or hormonal changes amplify insomnia susceptibility. In older adults, routine use of validated tools such as the Insomnia Severity Index (ISI) during annual assessments facilitates early detection, with education on and cognitive behavioral principles promoting non-pharmacological management to avert chronicity. For postpartum women, behavioral-educational interventions delivered prenatally and postnatally, including sleep diaries and relaxation techniques, enhance maternal duration and perceptions, reducing the trajectory toward persistent insomnia. These efforts often integrate into or maternity programs, emphasizing consistent routines and light exposure to align circadian rhythms. Brief behavioral interventions following trauma offer a targeted approach to prevent insomnia chronicity by addressing immediate sleep disruptions like and hyperarousal. Brief Behavioral Therapy for Insomnia (BBTI), a 4-session protocol incorporating and sleep restriction, significantly improves efficiency and reduces trauma-related in the acute phase, potentially halting progression to long-term disorders. Imagery Rehearsal Therapy (IRT), often delivered in 1-3 sessions, rewires content to diminish frequency and intensity, supporting overall consolidation post-trauma. Early implementation within 30 days of exposure maximizes prevention of PTSD-linked insomnia. Workplace policies promoting circadian health are vital for rotating shift workers, who face elevated insomnia risks due to irregular schedules. Evidence-based policies include optimized shift rotations with 4-5 recovery days between day and night shifts, combined with controlled bright light exposure during shifts and dim lighting post-shift to realign endogenous rhythms. Educational components, such as pre-shift napping guidelines and monitoring, further mitigate , with meta-analyses confirming moderate reductions in insomnia symptoms through these organizational adjustments. Implementing such policies via employer training enhances compliance and sustains workforce sleep health. Community-based programs addressing risks in focus on curbing screen-induced delays in onset, a common precipitant in adolescents. The Sleep Ninja app, a free CBT-I-based smartphone intervention co-developed with input, gamifies education and includes features to limit bedtime device use, such as automated notifications and relaxation modules, leading to improved duration and reduced disturbances in community trials. School-integrated initiatives promoting media-free zones before bed and peer-led workshops further reinforce these habits, targeting the high prevalence of evening screen exposure among , with nearly 99% of adolescents using screens in the two hours before bed, contributing to disturbances.

Treatment

Non-Pharmacological Approaches

Non-pharmacological approaches are prioritized as the first-line treatment for chronic and severe insomnia, emphasizing sleep hygiene habits such as maintaining regular sleep schedules, avoiding screens and caffeine at night, incorporating daytime exercise, and using relaxation techniques; patients should consult a healthcare provider to address underlying causes like stress or sleep apnea, with over-the-counter options like doxylamine or melatonin reserved for occasional use only. (CBT-I) is strongly recommended as the first-line treatment for chronic and severe insomnia by major organizations due to its robust evidence base and long-term benefits. Developed through foundational research in the 1990s and refined in subsequent decades, CBT-I typically involves 6 to 8 sessions and targets the cognitive, behavioral, and physiological factors perpetuating sleep difficulties. CBT-I is particularly effective for insomnia comorbid with anxiety disorders, simultaneously addressing sleep-specific issues and anxiety-related arousal, with trials showing reductions in both insomnia severity and anxiety symptoms. Key components include , which strengthens the association between the bed and sleep by instructing patients to leave the bedroom if unable to sleep after 20 minutes and to avoid non-sleep activities in bed; sleep restriction, which limits time in bed to match actual sleep time, gradually increasing it as sleep efficiency improves to consolidate sleep; and , which identifies and challenges maladaptive beliefs about sleep, such as catastrophic thinking about sleepless nights, to reduce anxiety and arousal. These elements work synergistically to break the cycle of insomnia, with education often integrated as an adjunct to promote consistent routines, including maintaining a consistent sleep schedule, limiting screen time before bed, avoiding late caffeine intake, and establishing a relaxing bedtime routine. Adjunctive relaxation techniques such as deep breathing, progressive muscle relaxation, and mindfulness meditation can further mitigate pre-sleep anxiety. To monitor progress, especially if sleep issues persist, patients can use a sleep diary or wearable devices to track sleep patterns. Clinical trials and meta-analyses demonstrate that CBT-I achieves improvement rates of 70-80% in reducing insomnia severity, with many patients experiencing sustained effects for up to 12 months or longer post-treatment, outperforming waitlist controls and showing comparable or superior durability to pharmacological options. For instance, response rates, defined as clinically significant reductions in insomnia symptoms, reach 70-80%, while remission rates hover around 40%, highlighting its potential for lasting resolution without reliance on ongoing intervention. These outcomes are supported by improvements in sleep efficiency, reduced , and enhanced daytime functioning, as evidenced across diverse populations including adults with chronic insomnia. For persistent issues, consultation with a healthcare professional is recommended to evaluate for underlying sleep disorders. Acceptance and Commitment Therapy (ACT), adapted for insomnia (ACT-I), offers an alternative psychological approach by emphasizing , acceptance of sleep-related thoughts and sensations, and commitment to value-driven behaviors rather than direct control over . ACT-I protocols typically include 6-8 sessions focusing on defusion from unhelpful sleep cognitions, present-moment awareness during routines, and aligning daily activities with personal values to mitigate insomnia's interference with life quality. Emerging evidence from randomized controlled trials indicates ACT-I yields moderate to large effects on insomnia severity and quality, comparable to CBT-I in some contexts, particularly for patients with high emotional avoidance or comorbid anxiety, with benefits persisting at 6-month follow-up. To enhance accessibility, internet-based and app-delivered CBT-I (iCBT-I or dCBT-I) have proliferated since 2020, delivering core components through guided modules, interactive tracking, and automated feedback via platforms accessible on smartphones or computers. Recent randomized trials from 2020-2025 show dCBT-I produces similar efficacy to in-person CBT-I, with 60-75% of users achieving clinically meaningful improvements in parameters and adherence rates exceeding 70% due to its self-paced, low-cost nature, making it suitable for underserved populations in remote or low-resource settings. These digital formats often incorporate elements like audio relaxations and progress dashboards, broadening reach without compromising therapeutic integrity. CBT-I can also be effectively delivered in group formats, typically involving 6-8 weekly sessions of 90 minutes each for 6-12 participants, fostering while covering the same core components through structured discussions and homework review. Group therapy maintains high efficacy, with meta-analyses reporting insomnia severity reductions equivalent to individual delivery, and it optimizes resource use in clinical settings. Therapists delivering CBT-I, whether individual or group, require specialized training, often at the master's level in , , or related fields, including 20-40 hours of didactic instruction, supervised practice, and fidelity monitoring to ensure adherence to evidence-based protocols, as outlined in certification programs from organizations like the Society of Behavioral Sleep Medicine.

Pharmacological Treatments

Pharmacological treatments for insomnia primarily target systems involved in regulation, offering symptomatic relief for sleep onset and maintenance difficulties. These medications are recommended for short-term use (typically ≤4 weeks) in adults with chronic insomnia, following guidelines from authoritative bodies like the (AASM), due to potential risks including dependence, tolerance, and next-day impairment. Treatment should be individualized and conducted under physician supervision, with strict adherence to sleep hygiene and avoidance of long-term use to prevent dependence and tolerance. Selection depends on patient-specific factors such as age, comorbidities, and insomnia subtype, with ongoing monitoring essential to balance efficacy and safety. For anxiety-related insomnia, short-term anti-anxiety medications or antidepressants may be combined with CBT-I or other therapies to address both conditions. Benzodiazepines (e.g., estazolam, clonazepam, temazepam) act by enhancing the inhibitory effects of gamma-aminobutyric acid (GABA) at GABA_A receptors in the , thereby facilitating sedation and reducing sleep latency. Temazepam is particularly useful for sleep maintenance insomnia, with clinical trials demonstrating improvements in total sleep time and wake after sleep onset compared to . However, their use is limited to short-term (typically 2-4 weeks) due to risks of , withdrawal symptoms upon discontinuation, and increased potential for falls and , especially in older adults. Long-term use has been associated with higher relapse rates and tolerance development in European cohort studies. Non-benzodiazepine hypnotics (Z-drugs), such as zolpidem, zopiclone, and zaleplon, selectively bind to the alpha-1 subunit of GABA_A receptors, mimicking effects but with a more targeted action to minimize daytime sedation. Zolpidem effectively reduces and increases efficiency in randomized controlled trials, often outperforming for subjective quality. Despite a lower risk of tolerance compared to benzodiazepines, Z-drugs carry concerns for complex sleep-related behaviors such as , , and hallucinations, particularly at higher doses or in vulnerable populations. Systematic reviews indicate these adverse neuropsychiatric effects occur in up to 10% of users, underscoring the need for lowest effective dosing. Melatonin receptor agonists, such as , promote sleep by selectively activating MT1 and MT2 melatonin receptors in the , thereby advancing circadian phase and improving sleep initiation without direct modulation. Clinical studies show reduces latency to persistent sleep by approximately 10-15 minutes over 5-6 weeks, with sustained efficacy in chronic insomnia patients. This class is considered safer for longer-term use, exhibiting a side effect profile comparable to , including minimal risk of dependence, next-day impairment, or abuse potential, making it suitable for older adults or those with hepatic concerns. Long-term trials confirm good tolerability, with and dizziness as the most common mild adverse events. Orexin receptor antagonists represent a newer class, with approved by the FDA in 2014 as the first dual antagonist (DORA) to treat insomnia. Subsequent approvals include in 2019 and in 2022, which similarly block and B from binding to OX1R and OX2R receptors, inhibiting wake-promoting pathways in the . By competitively blocking these receptors, , , and lead to increased total time and reduced wake after sleep onset in phase III trials. Post-2014 studies, including those up to 2023, demonstrate their efficacy in both sleep-onset and maintenance insomnia, with favorable safety profiles for up to 12 months, though and cataplexy-like symptoms occur in a minority of users. Unlike traditional hypnotics, this class preserves natural sleep architecture without rebound insomnia upon withdrawal. Comparative analyses, including meta-analyses of randomized trials, indicate that while pharmacological agents provide rapid short-term benefits, (CBT-I) yields superior long-term outcomes, with sustained improvements in sleep efficiency and lower relapse rates (e.g., 50-60% remission at 6-12 months versus 20-30% for drugs alone). Off-label use of sedating antidepressants, such as and mirtazapine (Remeron), may be considered for sleep issues, particularly in cases comorbid with depression or for short-term adjunctive use in severe insomnia; while low-dose doxepin is approved for sleep maintenance insomnia; however, for primary insomnia is limited and not superior to dedicated hypnotics, and certain antidepressants can suppress REM sleep, so their use should be discussed with a doctor. If pharmacological treatments prove ineffective, consultation with a healthcare provider is recommended for potential adjustments to the regimen, alternative medications, or transition to non-pharmacological approaches such as (CBT-I). For severe or refractory insomnia, referral to a sleep specialist for comprehensive assessment, individualized multimodal treatment, and concurrent management of underlying conditions (such as depression, anxiety, or pain) is recommended.

Alternative and Complementary Therapies

Alternative and complementary therapies for insomnia encompass a range of non-pharmacological interventions, including herbal remedies, , mind-body practices, and , which aim to improve quality through mechanisms outside conventional medical treatments. These approaches often appeal to individuals seeking natural options, though evidence varies in strength and consistency across studies. While some randomized controlled trials (RCTs) and meta-analyses indicate modest benefits, particularly for subjective improvements, rigorous long-term data remain limited. Herbal remedies such as valerian root and have been investigated for their potential to alleviate insomnia symptoms. Evidence for valerian root extracts, derived from the Valeriana officinalis plant, is mixed; some older RCTs suggested modest improvements in subjective sleep quality, though effects were more pronounced in subjective reports than objective measures like . However, a 2024 umbrella review found insufficient evidence of efficacy for treating insomnia despite a good safety profile when used short-term, and it does not support routine use. , often consumed as tea from Matricaria recutita flowers, has shown promise in improving sleep quality among elderly populations, with an RCT involving 60 participants reporting significant reductions in (PSQI) scores after four weeks of daily use. These herbs may act via sedative properties, such as modulation for valerian, but results are inconsistent across populations, with some meta-analyses noting insufficient evidence for broad recommendations. Acupuncture, a traditional Chinese medicine technique involving needle insertion at specific points, has been studied for its role in treating insomnia through potential mechanisms like endorphin release and regulation. Meta-analyses of RCTs indicate that significantly improves sleep quality, as measured by PSQI scores, particularly after more than three weeks of treatment, with effect sizes suggesting superiority over sham acupuncture in reducing insomnia severity. For example, a review of 46 RCTs involving over 3,500 patients found effective for chronic insomnia disorder, improving total time and efficiency, though benefits may wane without ongoing sessions. The endorphin-mediated pain relief and stress reduction aspects are hypothesized to contribute to better sleep onset, but high-quality trials are needed to confirm long-term efficacy. Mind-body practices like and offer structured protocols to enhance by promoting relaxation and reducing hyperarousal. , involving postures, breathing, and , has been evaluated in RCTs showing improvements in and overall quality, with of 16 trials reporting significant PSQI reductions in women with disturbances. Specific protocols, such as 45-60 minute sessions twice weekly for 8-12 weeks focusing on restorative poses like child's pose and savasana, yield the most consistent results. Similarly, , a gentle art emphasizing slow movements and , improves quality in healthy adults and those with chronic conditions, with a of nine RCTs demonstrating an of 0.89 for PSQI improvements after 6-24 weeks of 1.5-3 hours weekly practice. These interventions may work by lowering levels and enhancing parasympathetic activity, though adherence to protocols is crucial for outcomes. Light therapy, using bright light exposure to realign circadian rhythms, has emerging evidence for insomnia in non-depressed patients, particularly those with delayed sleep phase or maintenance issues. A meta-analysis of 13 RCTs found that timed morning or evening exposure (typically 2,500-10,000 for 30-60 minutes) significantly reduced wake after onset and improved total time compared to control conditions, without exacerbating mood symptoms in non-depressed individuals. This approach leverages the suprachiasmatic nucleus's response to for phase advancement, offering a non-invasive option for circadian misalignment, though optimal timing varies by . Despite potential benefits, alternative therapies face limitations, including lack of regulation by the FDA for herbal products, which can lead to variability in potency and purity. The FDA does not require pre-market approval for dietary supplements like valerian or , raising concerns about contamination or inconsistent dosing. Additionally, herb-drug interactions pose risks; for example, valerian may enhance sedative effects of medications like benzodiazepines, increasing drowsiness or respiratory depression, as noted in NIH reviews of common interactions. Patients should consult healthcare providers to mitigate these risks, and while these therapies can complement approaches like CBT-I, they are not substitutes for evidence-based treatments.

Prognosis

Short-Term Outcomes

Acute insomnia, defined as sleep difficulties lasting less than , frequently resolves spontaneously without intervention. Studies indicate that approximately 72% of individuals experiencing acute insomnia recover normal patterns, often within weeks, particularly when the underlying trigger is transient. This high rate of spontaneous remission underscores the self-limiting nature of many acute cases, where sleep disturbances subside as the precipitating factors diminish. However, about 7% of acute cases progress to chronic insomnia, highlighting the importance of early monitoring to identify those at risk. Brief interventions, such as education, offer effective support for short-term recovery in acute insomnia. These approaches, which emphasize consistent sleep schedules, environmental adjustments, and avoidance of stimulants, yield notable improvements in and overall efficiency. Research on behavioral interventions incorporating principles demonstrates rapid reductions in insomnia severity, with benefits observed within one week and sustained short-term gains in approximately 60-70% of participants reporting enhanced sleep quality. Such interventions are particularly valuable for mild to moderate acute cases, promoting quicker resolution compared to no treatment. Post-treatment relapse risks in short-term insomnia outcomes are elevated in the presence of untreated comorbidities, such as anxiety or pain disorders. Untreated co-occurring conditions can perpetuate sleep disruptions; studies indicate that approximately 27% of individuals who achieve remission of insomnia symptoms may experience over time. Addressing these comorbidities concurrently reduces likelihood, emphasizing integrated care for optimal short-term prognosis. Monitoring short-term outcomes typically involves sleep diaries, which track key metrics like sleep latency, duration, and efficiency over 1-3 months. These self-reported tools provide objective insights into progress, revealing patterns such as reduced wake time after sleep onset in responding individuals. Consistent diary use facilitates early detection of non-remission, guiding adjustments to interventions. Several factors influence the speed and likelihood of recovery from acute insomnia. Resolution of the precipitating stressor, such as job loss or illness, often correlates with prompt improvement, as sleep normalizes once the acute threat abates. Age also plays a role, with older adults experiencing slower recovery due to age-related changes in sleep architecture and higher burdens, potentially extending resolution beyond the typical weeks. Younger individuals, conversely, tend to rebound more swiftly absent complicating factors.

Long-Term Implications

Persistent insomnia is associated with an elevated risk of cardiovascular diseases, including coronary heart disease and , as evidenced by cohort studies showing ratios ranging from 1.37 to 1.82 for incident cardiovascular events among those with chronic disturbances. Similarly, insomnia contributes to a higher incidence of , with prospective data indicating an ratio of 1.37 for new-onset cases, potentially mediated by activation and elevated resting . For , chronic insomnia has been linked to approximately 50% increased of , a key precursor, based on large-scale cohort analyses. The relationship between insomnia and is bidirectional, with insomnia serving as both a precursor and consequence of depression; meta-analyses of longitudinal studies report an of 2.60 for insomnia predicting future depression onset, while persistent insomnia in those without initial depression elevates the risk up to sixfold. In older adults, untreated insomnia is further implicated in cognitive decline and , with cohort studies demonstrating faster rates of and a significantly heightened risk of , attributed to disrupted sleep's impact on amyloid-beta clearance and . Effective treatments like (CBT-I) can improve long-term prognosis, with meta-analyses showing 70-80% remission rates sustained over years. Economically, the long-term effects of insomnia manifest in substantial lost productivity, with estimates from national workforce studies indicating an annual cost of $207.5 billion as of 2023 due to and reduced . Globally, this burden extends into the hundreds of billions, encompassing indirect societal costs from impaired daily functioning. Meta-analyses of prospective cohorts link persistent insomnia to a 10-20% higher all-cause mortality , with pooled showing a 14% increase, particularly when combined with short duration, independent of comorbidities like .

Epidemiology

Prevalence and Demographics

Insomnia is a widespread affecting a significant portion of the global population. Estimates indicate that 10-30% of adults insomnia symptoms, such as difficulty initiating or maintaining , while 6-10% meet the criteria for insomnia disorder according to diagnostic standards like the or ICSD-3. Recent systematic reviews, incorporating post-pandemic , suggest a global prevalence of insomnia disorder around 16%, with severe cases at approximately 8%, reflecting an increase linked to stressors like COVID-19. These figures underscore the condition's substantial impact, though exact rates vary due to methodological differences in assessment. Demographic variations highlight disparities in insomnia . Women are disproportionately affected, with rates 1.5 to 2 times higher than in men across age groups, attributed to factors like hormonal changes and higher rates of comorbid conditions. tends to peak in midlife (ages 35-49) and among the elderly (over 60), where up to 40-50% report symptoms, often exacerbated by age-related changes in architecture and health issues. Among pediatric and adolescent populations, rates range from 15-25%, with recent trends showing increases, particularly post-2020, due to and academic pressures. Regional differences further influence prevalence patterns. Urban residents often report higher rates of insomnia (around 20%) compared to rural areas (15-17%), potentially due to noise, , and stressors, though some studies note elevated trouble falling asleep in rural settings. appears more documented in high-income countries, where systematic surveys yield rates of 10-20%, compared to lower-middle-income regions, though underreporting in low-resource areas may skew global comparisons. Survey methodologies contribute to discrepancies in reported prevalence. Self-report tools, such as questionnaires like the Insomnia Severity Index, often yield higher estimates (up to 29%) than clinical diagnoses or interviews (around 6-12%), as individuals may overestimate sleep disturbances without objective confirmation via . These differences highlight the need for standardized diagnostic approaches to accurately capture the disorder's true burden. The contributed to a notable rise in global insomnia prevalence, with studies attributing this to heightened stress, anxiety, and measures. A multinational collaborative reported symptomatic insomnia rates of 36.7% and clinical insomnia disorder at 17.4% during the , representing an increase from pre- global estimates of approximately 10-15%. Similarly, an international review estimated the average prevalence of post-COVID-19 insomnia at around 24%, with persistence observed in cases. These trends highlight a 20-30% relative uptick in affected populations in various regions, exacerbating the overall burden. Socioeconomic disparities amplify the insomnia burden, with higher observed among low-income groups due to factors like financial strain and unstable living conditions. indicates that lower correlates with increased insomnia risk, including shorter sleep duration and poorer quality, particularly in urban low-SES communities. In developing regions, limited healthcare further restricts access to and treatment, resulting in untreated cases and compounded health impacts. Racial and ethnic minorities within these groups often face intersecting vulnerabilities, such as neighborhood , which mediates higher odds of insomnia disorder. Cultural influences play a role in under-reporting insomnia worldwide, as stigma in certain societies portrays sleep issues as personal weaknesses or moral failings, deterring individuals from seeking help. Qualitative studies reveal that internalized and anticipated stigma is linked to self-reported sleep deficiencies, including insomnia symptoms, across diverse cultural contexts. This is particularly evident in collectivist cultures where discussions, including , remain , leading to lower detection rates. Access to insomnia care varies globally, with under-diagnosis common in primary care settings where providers often overlook sleep complaints unless explicitly raised by patients. Post-2020 telehealth expansions have mitigated some barriers, enabling remote delivery of evidence-based interventions and improving outcomes in underserved areas. Systematic reviews confirm telemedicine's efficacy in treating insomnia, with positive effects on sleep parameters comparable to in-person care. Policy efforts address these disparities through international frameworks integrating sleep health into mental health priorities. The World Health Organization's Comprehensive Mental Health Action Plan 2013–2030 emphasizes holistic approaches that include sleep promotion to enhance global mental well-being, though implementation remains uneven across low-resource settings. Additional calls advocate for public health policies targeting sleep education and equitable access to reduce the insomnia gap.

Society and Culture

Historical Perspectives

In ancient times, descriptions of insomnia, referred to as "sleeplessness," appeared in early medical texts, with around 400 BC linking it to imbalances in the body's humors, such as excess or disrupting natural rest. Hippocratic physicians viewed insomnia as a symptom of broader physiological disturbances and recommended soporific remedies, like herbal concoctions, to restore humoral equilibrium and promote , though specific formulations were not detailed in surviving writings. This humoral theory dominated Western medical thought on sleep disorders for centuries, framing insomnia as a treatable imbalance rather than a standalone condition. By the 19th and early 20th centuries, insomnia emerged as a recognized psychiatric entity, often classified under neuroses or anxiety-related disorders in emerging psychiatric nosologies. The introduction of barbiturates in the early 1900s, starting with in 1903, marked a pharmacological shift, positioning these sedatives as primary treatments for insomnia due to their ability to induce in psychiatric patients. However, their narrow led to widespread risks, including overdose deaths and dependency, prompting caution in clinical use by the mid-20th century as reports of toxicity accumulated. The mid-20th century witnessed a pivotal shift toward as a distinct field, driven by electroencephalogram (EEG) discoveries that revealed sleep's physiological stages. In the 1950s, researchers like Eugene Aserinsky and identified rapid eye movement (REM) sleep through EEG monitoring, demonstrating cyclical brain activity patterns and challenging prior psychiatric views of insomnia as purely psychological. This work, building on earlier EEG observations of non-REM stages in the 1930s, established sleep as a measurable neurobiological process, laying the foundation for and specialized clinics by the 1970s. From the 1980s to the 2000s, (CBT-I) evolved as a , integrating techniques like and sleep restriction, with key developments in the late 1980s formalizing its structured protocol. Concurrently, Diagnostic and Statistical Manual of Mental Disorders (DSM) classifications refined insomnia's : DSM-III (1980) introduced it as a separate disorder, DSM-III-R (1987) specified diagnostic criteria, and DSM-IV (1994) distinguished primary insomnia from comorbid forms, emphasizing duration and impairment. These advancements highlighted insomnia's chronic nature and behavioral underpinnings. In recent milestones, the 1998 discovery of neuropeptides, which regulate wakefulness, spurred development of orexin receptor antagonists; , the first such drug, gained FDA approval in 2014 for insomnia treatment, offering a targeted mechanism distinct from traditional sedatives.

Public Awareness and Stigma

Public awareness of insomnia has grown in recent decades, yet misconceptions persist, often portraying it in media as a mere rather than a serious condition. In and , insomnia is frequently depicted as a hindrance to , with sleepless characters grappling with impaired focus and daily functioning amid modern life's demands, as seen in Hollywood narratives where it symbolizes the toll of relentless ambition. For instance, in science fiction works, underscores themes of consciousness and survival, while in modernist like Franz Kafka's writings, it both torments and fuels creative output, though rarely shown as treatable. Occasionally, media uses insomnia for , exaggerating symptoms in comedies to highlight quirky exhaustion, which minimizes its clinical reality and reinforces stereotypes of it as a personal failing rather than a disorder. Stigma surrounding insomnia significantly impacts help-seeking behaviors, with many perceiving it as a sign of weakness or laziness, leading to under-reporting and delayed treatment. Studies indicate that up to 81% of individuals with chronic insomnia disorder experience stigma, including internalized shame and enacted , which correlates with longer illness duration and poorer outcomes. This perception contributes to reluctance in discussing issues with clinicians, with approximately 30% of those affected hesitating due to stigma and 45% avoiding medication options, exacerbating the condition's untreated prevalence. Such barriers, rooted in societal biases, not only prolong suffering but also widen disparities, as stigmatized individuals often dismiss symptoms as temporary stress rather than seeking professional care. Advocacy efforts by organizations like the have aimed to combat these issues through targeted campaigns, such as Sleep Awareness Week held annually in March, which educates the public on sleep's role in well-being, productivity, and happiness. These initiatives highlight research showing poor sleep doubles risks to work performance and social life, encouraging lifestyle changes and policy advocacy to normalize sleep health discussions. On the economic and policy front, insomnia features prominently in programs, where employers implement education, flexible scheduling, and to reduce costs—estimated at over $2,000 per untreated employee annually—and boost overall productivity. Such programs, supported by guidelines from bodies like the CDC, reflect growing recognition of insomnia's role in occupational health, with over half of large U.S. employers planning expansions by 2021. Cultural variations further shape perceptions of insomnia, influencing how it is framed as an individual versus communal concern. European surveys reveal similar disparities; for example, respondents report greater work-related impacts (85%) compared to French individuals (lower relational effects at 51%), with overall trivialization delaying care across regions. These differences underscore the need for culturally tailored to address insomnia effectively.

References

Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.